Natco Pharma Limited
A vertically integrated pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. Natco Pharma operates across three core business segments: finished dosage formulations, active pharmaceutical ingredients, and contract manufacturing services. The company maintains a strong research and development focus to drive innovation and develop specialized therapeutic solutions across oncology, cardiovascular, gastroenterology, and other critical therapeutic domains.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.